🇺🇸 FDA
Pipeline program

Placebo to match Linaprazan glurate 50mg, Placebo to match Lansoprazole 30 mg, Linaprazan glurate, LANSOPRAZOLE

CX842A2301

Phase 3 small_molecule active

Quick answer

Placebo to match Linaprazan glurate 50mg, Placebo to match Lansoprazole 30 mg, Linaprazan glurate, LANSOPRAZOLE for Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials